Scimago Lab
powered by Scopus
eISSN: 1941-5923
call: +1.631.629.4328
Mon-Fri 10 am - 2 pm EST


Medical Science Monitor Basic Research


Treatment with Recombinant Factor XIII (Tretten) in a Pregnant Woman with Factor XIII Deficiency

Unusual setting of medical care, Unexpected drug reaction , Rare disease, Educational Purpose (only if useful for a systematic review or synthesis)

Nizar Abdel-Samad

Canada Department of Internal Medicine, The Moncton Hospital, Moncton, NB, Canada

Am J Case Rep 2017; 18:436-439

DOI: 10.12659/AJCR.901502

Available online:

Published: 2017-04-22

BACKGROUND: Factor XIII deficiency is associated with recurrent miscarriages in women.
CASE REPORT: In this report, we present a patient with factor XIII deficiency and some comorbidities who had had previous miscarriages. She began treatment with factor XIII subunit A (XIII-A) replacement treatment Recombinant factor XIII (Tretten) at a dose of 2500 units monthly and was able, for the first time, to carry a pregnancy almost to term. Although she experienced some obstetrical complications, she delivered a healthy baby. To the best of our knowledge, this is the first report of the use of Tretten during pregnancy.
CONCLUSIONS: Tretten, which is not indicated in pregnancy, offered a safe, effective treatment for miscarriages secondary to factor XIII-A deficiency in our patient. Further research is required to confirm this finding.

Keywords: Abortion, Spontaneous, Factor XIII Deficiency, Pregnancy Complications, Hematologic